<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02736240</url>
  </required_header>
  <id_info>
    <org_study_id>022152015003</org_study_id>
    <nct_id>NCT02736240</nct_id>
  </id_info>
  <brief_title>Immunogenicity and Safety Study of the 13-valent Pneumococcal Polysaccharide Conjugate Vaccine in 2-71 Months Old Healthy Infants and Toddlers (the Youngest Could be 6 Weeks Old)</brief_title>
  <official_title>Immunogenicity and Safety Study of the 13-valent Pneumococcal Polysaccharide Conjugate Vaccine Developed Cooperatively by YunNan Walvax Biotechnology Co., Lt and Yuxi Walvax Biotechnology Co., Lt Among 2-71 Months (the Youngest Could be 6 Weeks) Healthy Infants and Toddlers by Randomized Blind Method With Similar Control in Multi-centers.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Walvax Biotechnology Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Walvax Biotechnology Co., Ltd.</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate and valuate the immunogenicity and safety of the
      13-valent pneumococcal polysaccharide conjugate vaccine in 2-71 months old healthy infants
      and toddlers (the youngest could be 6 weeks old)
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>April 2016</start_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the rate of the immunoglobulin G ≥0.35μg/ml in the subjects with the full series of doses</measure>
    <time_frame>30 days after finishing the infants doses and the toddlers doses (if necessary)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>the geometrical mean concentration(GMC) of the immunoglobulin G in the subjects with the full series of doses</measure>
    <time_frame>30 days after finishing the infants doses and the toddlers doses (if necessary)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>the incidence of the local adverse reactions and the systematic adverse reactions</measure>
    <time_frame>30 days after finishing the infants doses and the toddlers doses (if necessary)</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">2760</enrollment>
  <condition>Diseases Caused by Streptococcus Pneumoniae Serotypes</condition>
  <arm_group>
    <arm_group_label>Control Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>7-valent pneumococcal conjugate vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Test Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>13-valent pneumococcal conjugate vaccine</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>7-valent pneumococcal conjugate vaccine</intervention_name>
    <arm_group_label>Control Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>13-valent pneumococcal polysaccharide conjugate vaccine</intervention_name>
    <arm_group_label>Test Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  2-71 months (the youngest could be 6 weeks old) infants or toddlers which are
             positively healthy based on the medical history, the physical examination and the
             judgment of the investigator;

          -  The statutory guardian (or the consignor) of the subject agree his/her child
             participate in the study, and is willing to sign the informed consent form;

          -  The subject and his/her statutory guardians (or the consignor) are able to comply with
             the requests of the clinical study protocol;

          -  Never be immunized with any pneumococcus vaccine, and didn't get immunization with any
             other preventive product in the past 10 days (didn't get immunized with attenuated
             live vaccine in the past 14 days);

          -  The auxillary temperature ≤37℃.

        Exclusion Criteria:

          -  Has already been immunized with pneumococcus vaccine no matter it is experimental or
             marketed;

          -  With the history of invasive disease caused by streptococcus pneumonia by culture;

          -  With the history of serious allergy to any vaccine or drug, has got fever higher than
             39℃ related to immunization with preventive biological product;

          -  Infant that the birth weight is lighter than 2.5 kg;

          -  With the history or the family history of seizure, epilepsy, cerebropathy and
             psychosis ;

          -  Infant with the abnormal labor (difficult labor, deliver with apparatus) or with the
             history of asphyxia or nervous damage;

          -  With the history of thrombocytopenia or other coagulation disorders by definite
             diagnosis;

          -  Infant or toddler with pathological jaundice by diagnosis;

          -  Be known with or suspected with immunological dysfunction, including immunosuppressive
             therapy (radiotherapy, chemotherapy, corticosteroid hormone, antimetabolites,
             cytotoxic drug), HIV infection etc. ;

          -  Be known with serious congenital malformation or serious chronic disease; suffer from
             congenital malformation or be diagnosed with serious chronic disease (eg. Down
             syndrome, diabetes mellitus, sickle cell anemia or nervous disease, Guillain-Barre
             syndrome);

          -  Be known with or suspected with diseases including: disease of respiratory system,
             acute infection or the active period of chronic disease, serious cardiovascular
             disease, hepatic-nephrotic disease, malignant tumor, skin disease;

          -  Has taken blood product or globulin (the hepatitis B immune globulin is allowed);

          -  Be participating in other clinical trials;

          -  Any other situation which is considered to influence the evaluation of the study by
             investigators .
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Months</minimum_age>
    <maximum_age>71 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Shuyuan Yang, Master</last_name>
    <phone>8618687832269</phone>
    <email>ynwsysy@walvax.com</email>
  </overall_contact>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 31, 2016</study_first_submitted>
  <study_first_submitted_qc>April 7, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 13, 2016</study_first_posted>
  <last_update_submitted>April 7, 2016</last_update_submitted>
  <last_update_submitted_qc>April 7, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 13, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

